Chhattisgarh has attracted pharmaceutical investment proposals worth Rs. 992.53 crore over the past 18 months under its Industrial Development Policy 2024–30, with four projects worth Rs. 216 crore already under implementation.

The projects, being developed by 9M India, Shankara Latex Industries, Avila Pharmaceuticals, and Vitalis Health Services, are at various stages of execution. 

Manufacturing facilities being set up by 9M India and Shankara Latex Industries are under construction and expected to become operational soon, while projects by Avila Pharmaceuticals and Vitalis Health Services are also progressing steadily.

The early transition from investment proposals to on-ground execution is significant for the pharmaceutical sector, where manufacturing projects typically involve long gestation periods and careful investment decisions.

The investment momentum follows Chhattisgarh's recognition as the top-ranked large state in NITI Aayog's Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, highlighting its improving business climate.

"Chhattisgarh is consciously diversifying its industrial landscape, and pharmaceuticals are among the new-age sectors we are ready to host at scale. The momentum we're seeing in Nava Raipur reinforces the confidence investors are placing in the state's readiness for advanced manufacturing and validates our sustained focus on ease of doing business," said Chief Minister Vishnu Deo Sai.

Under the Industrial Development Policy 2024–30, pharmaceuticals have been designated as a thrust sector. 

The policy provides capital assistance linked to investment size, reimbursement of net SGST for up to 12 years, exemptions on electricity duty and stamp duty, and additional incentives for pioneer investors to improve project viability and encourage long-term manufacturing investments.

The state's investment ecosystem has also been strengthened by the enactment of the Chhattisgarh Ease of Doing Business Act, 2026, making it the first state in India to introduce a risk-based regulatory framework aimed at simplifying approvals, reducing compliance requirements, and accelerating project implementation.

A key driver of this growth is the Pharma Park at Nava Raipur, spread across nearly 142 acres and equipped with plug-and-play infrastructure, common utilities, and logistics connectivity. Since opening plot allotments just over a year ago, the park has allotted seven plots, reflecting growing investor interest and steady progress in developing Nava Raipur as a pharmaceutical manufacturing hub.